4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺鈉鹽
| 中文名稱 | 4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺鈉鹽 |
|---|---|
| 中文同義詞 | 4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺鈉鹽;((4-氨基苯基)磺酰基)(6-氯吡嗪-2-基)酰胺鈉;化合物 SULFACLOZINE SODIUM;Sulfaclozine (sodium salt),Reagent;抑制劑Sodium Sulfaclozine;抑制劑Sodium Sulfaclozine |
| 英文名稱 | sodium N-(6-chloropyrazinyl)sulphanilamidate |
| 英文同義詞 | sodium N-(6-chloropyrazinyl)sulphanilamidate;4-Amino-N-(6-chloro-2-pyrazinyl)benzenesulfonamide sodium salt;Sodium ((4-aminophenyl)sulfonyl)(6-chloropyrazin-2-yl)amide;Sulfaclozine (sodium salt);C16990045 SulfachloropyrazinEsodium;Sulfaclozine (sodium salt),Reagent;Sulfachloropyrazine sodium 100 μg/mL in Acetonitrile;Sulfaclozine sodium monohydrate |
| CAS號 | 23307-72-4 |
| 分子式 | C10H10ClN4NaO2S |
| 分子量 | 308.72 |
| EINECS號 | 245-571-9 |
| 相關(guān)類別 | |
| Mol文件 | 23307-72-4.mol |
| 結(jié)構(gòu)式 |  |
4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺鈉鹽 性質(zhì)
| 儲存條件 | under inert gas (nitrogen or Argon) at 2–8 °C |
|---|---|
| 溶解度 | DMF：1mg/mL； DMSO：1mg/mL； PBS（pH 7.2）：1 mg/mL |
| 形態(tài) | 固體 |
| 顏色 | 淺黃至黃色 |
| 主要應(yīng)用 | 臨床測試 |
| InChI | 1S/C10H8ClN4O2S.Na/c11-9-5-13-6-10(14-9)15-18(16,17)8-3-1-7(12)2-4-8;/h1-6H,12H2;/q-1;+1 |
| InChIKey | NIUFFODHMKLSCH-UHFFFAOYSA-N |
| SMILES | Nc1ccc(cc1)S(=O)(=O)N([Na])c2cncc(Cl)n2 |
Bacterial; Parasite
The elimination of Sulfaclozine in the three systems: UV/TiO 2 , UV/K 2 S 2 O 8 , and UV/TiO 2 /K 2 S 2 O 8 . Sulfaclozine is weakly adsorbed on the surface of TiO 2 at pH 7 (< 5%) but efficiently eliminated with the following three systems: UV/TiO 2 , UV/K 2 S 2 O 8 , and UV/TiO 2 /K 2 S 2 O 8 in ultra pure water. Moreover, 12 of Sulfaclozine by-products are identified and reaction pathways show that, in addition of ? OH and SO 4 ?? radicals, the conduction-band electrons are responsible for the formation of some main by-products either directly or by the formation of superoxide radicals.
Sulfaclozine (60 mg/kg; intravenous injection or oral administration; male broiler chickens) can be used primarily for the treatment of parasitic and microbial infections of the digestive tract rather than for the treatment of systemic infections.
| Animal Model: | 14 male broiler chickens (30-day-old) |
| Dosage: | 60 mg/kg |
| Administration: | Intravenous injection or oral administration (Pharmacokinetic Analysis) |
| Result: | Serum drug concentrations at 0.083, 0.50, 2, 6, 24 and 72h were determined to be 99.62, 83.50, 72.68, 58.43, 38.66 and 13.14 μg/mL, respectively, by intravenous injection. By oral administration were determined as 4.33, 7.95, 16.46, 22.88, 16.03 and 5.74 μg/mL, respectively. |
安全信息
| WGK Germany | 3 |
|---|---|
| 存儲類別 | 11 - 可燃固體 |
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-19285AR | 4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺鈉鹽 Sulfaclozine sodium (Standard) | 23307-72-4 | 10 mg | 300元 |
| 2026/06/05 | HY-19285AR | 4-氨基-N-(6-氯-2-吡嗪基)苯磺酰胺鈉鹽 Sulfaclozine sodium (Standard) | 23307-72-4 | 25 mg | 550元 |